Bio-Rad Labs (BIO) Tops Q2 EPS by 88c

Bio-Rad Labs (NYSE: BIO) reported Q2 EPS of $3.54, $0.88 better than the analyst estimate of $2.66. Revenue for the quarter came in at $715.9 million versus the consensus estimate of $631.78 million.

2021 Financial Outlook:

For the full year 2021, the company has updated its guidance and now anticipates non-GAAP currency-neutral revenue growth between 10.0 to 10.5 percent and an estimated non-GAAP operating margin of approximately 19.0 percent. Management will discuss this outlook in greater detail on the second-quarter 2021 financial results conference call.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.

You May Also Be Interested In

• Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
• Stifel Positive on Rapport Therapeutics (RAPP): 'remains on track to share longer-term safety data from the ph2a in 4Q26'
• Leidos Holdings (LDOS) PT Lowered to $138 at Stifel